Form 8-K - Current report:
SEC Accession No. 0001493152-22-034831
Filing Date
2022-12-08
Accepted
2022-12-08 09:25:31
Documents
21
Period of Report
2022-12-08
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 42920
2 ex99-1.htm EX-99.1 30781
3 ex99-2.htm EX-99.2 989
4 ex99-3.htm EX-99.3 1142
5 ex99-4.htm EX-99.4 1016
6 ex99-1_001.jpg GRAPHIC 11458
7 ex99-2_001.jpg GRAPHIC 729672
8 ex99-3_001.jpg GRAPHIC 3020679
9 ex99-4_001.jpg GRAPHIC 3194194
  Complete submission text file 0001493152-22-034831.txt   9879763

Data Files

Seq Description Document Type Size
10 XBRL SCHEMA FILE bct-20221208.xsd EX-101.SCH 3949
11 XBRL DEFINITION FILE bct-20221208_def.xml EX-101.DEF 26582
12 XBRL LABEL FILE bct-20221208_lab.xml EX-101.LAB 36619
13 XBRL PRESENTATION FILE bct-20221208_pre.xml EX-101.PRE 25206
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5393
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 221451546
SIC: 2834 Pharmaceutical Preparations